A wave of disappointing third-quarter results and clinical trial failures by the largest biotechs in late October 2017 signaled to some the start of another market swoon, akin to the one that dented share prices starting in late 2015 through 2016.
SUBSCRIBE
Biohealth Innovation
Founding Member of
